Table 4.
Summary of cardiac PET findings in subjects with CS (N = 12*)
| FLT-PET | FDG-PET | p value | |
|---|---|---|---|
| # of subjects with cardiac uptake (%) | 6 (50%) | 7 (58%) | 0.70 |
| # of LV segments involved ± SD | 6.2 ± 1.5 | 7.3 ± 3.5 | 0.50 |
| # of segments in LAD† territory ± SD | 2.5 ± 1.0 | 2.7 ± 1.3 | 0.75 |
| # of segments in LCX territory ± SD | 1.3 ± 1.0 | 1.7 ± 1.4 | 0.59 |
| # of segments in RCA territory ± SD | 2.5 ± 0.8 | 2.9 ± 1.5 | 0.61 |
| # of subjects with RV uptake (%) | 2 (17%) | 4 (33%) | 0.17 |
| Maximum LV SUV ± SD | 15.4 ± 4.4 | 13.7 ± 6.0 | 0.58 |
| LV SUVTotal ± SD | 27.7 ± 8.4 | 45.7 ± 33.1 | 0.22 |
| Maximum RV SUV ± SD α | 2.4 ± 0.4 | 4.6 ± 5.0 | 0.59 |
| Perfusion PET | |||
| # of subjects with perfusion defects (%) | 10 (83%) | ||
| SRS ± SD | 6.2 ± 4.6 | ||
| SRS in LAD territory ± SD | 3.2 ± 2.9 | ||
| SRS in LCX territory ± SD | 1.0 ± 1.3 | ||
| SRS in RCA territory ± SD | 2.0 ± 1.9 | ||
LV left ventricle, RV right ventricle, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, SUV standardized uptake value
*Only subjects satisfying the HRS criteria (N = 12/14) were included in this analysis
†Vascular territories defined as per AHA 17 segment model [13]
αIncludes only those subjects with evidence of RV uptake